Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of labelled compounds & radiopharmaceuticals

• Publication date

  2018-07-01

• Fields of study

  Medicine, Chemistry, Engineering

• Identifiers
  DOI 10.1002/jlcr.3612PMID 29412489PMCID PMC6081268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Generalized PSF modeling for optimized quantitation in PET imaging

  2017cited by this paper
• Whole-Brain Microscopy Meets In Vivo Neuroimaging: Techniques, Benefits, and Limitations

  2017cited by this paper
• Cerenkov luminescence imaging: physics principles and potential applications in biomedical sciences

  2017cited by this paper
• Multiplexed imaging for diagnosis and therapy

  2017cited by this paper
• Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers

  2017cited by this paper
• Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

  2017cited by this paper
• Proceedings of the World Molecular Imaging Congress 2017, Philadelphia, Pennsylvania, September 13-16, 2017: General Abstracts

  2017cited by this paper
• Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer

  2017cited by this paper
• Current status and perspectives of patient-derived xenograft models in cancer research

  2017cited by this paper
• The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?

  2017cited by this paper
• Choosing wisely - Preclinical test models in the era of precision medicine.

  2017cited by this paper
• Pretargeted Imaging and Therapy

  2017cited by this paper
• Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors

  2017cited by this paper
• The Future of Radioligand Therapy: α, β, or Both?

  2017cited by this paper
• Effect of charge localization on the in vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates.

  2016cited by this paper
• Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET.

  2016cited by this paper
• Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

  2016cited by this paper
• Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses

  2016cited by this paper
• Mouse models in oncoimmunology

  2016cited by this paper
• Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

  2016cited by this paper
• Engineering antibody therapeutics.

  2016cited by this paper
• Both Complexity and Location of DNA Damage Contribute to Cellular Senescence Induced by Ionizing Radiation

  2016cited by this paper
• Engineered IgG1‐Fc – one fragment to bind them all

  2016cited by this paper
• Antibodies to watch in 2017

  2016cited by this paper
• Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.

  2016cited by this paper
• DNA double-strand break repair: a theoretical framework and its application

  2016cited by this paper
• A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting.

  2016cited by this paper
• Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.

  2016cited by this paper
• Phage display-derived human antibodies in clinical development and therapy

  2016cited by this paper
• Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry

  2016cited by this paper
• Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization

  2016cited by this paper
• Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

  2016cited by this paper
• Examining the utility of patient-derived xenograft mouse models

  2015cited by this paper
• Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

  2015cited by this paper
• Preclinical mouse cancer models: a maze of opportunities and challenges.

  2015cited by this paper
• Organoid models of human and mouse ductal pancreatic cancer.

  2015cited by this paper
• Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

  2015cited by this paper
• Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts

  2015cited by this paper
• A nuclear chocolate box: the periodic table of nuclear medicine.

  2015cited by this paper
• DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance in bone targeting radiotherapy: a new class of “DOTA-BPretard” tracers

  2015cited by this paper
• Translational value of mouse models in oncology drug development

  2015cited by this paper
• The therapeutic monoclonal antibody market

  2015cited by this paper
• aHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo

  2015cited by this paper
• Targeting the tumor niche to treat cancer

  2015cited by this paper
• 18F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels–Alder Click Chemistry

  2015cited by this paper
• A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?

  2015cited by this paper
• A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

  2015influential reference
• Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.

  2015cited by this paper
• Radioimmunotherapy of human tumours

  2015cited by this paper
• Radioimmunotherapy of human tumours

  2015influential reference
• 89Zr-Labeled Versus 124I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo

  2015cited by this paper
• Pretargeted imaging using bioorthogonal chemistry in mice.

  2014cited by this paper
• Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

  2014cited by this paper
• In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.

  2014cited by this paper
• Patient-derived xenograft models: an emerging platform for translational cancer research.

  2014cited by this paper
• Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry

  2014cited by this paper
• ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116

  2014cited by this paper
• Targeted alpha-particle immunotherapy for acute myeloid leukemia.

  2014cited by this paper
• 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

  2014cited by this paper
• Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

  2014cited by this paper
• Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies

  2014cited by this paper
• Human cancer growth and therapy in immunodeficient mouse models.

  2014cited by this paper
• Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody

  2014cited by this paper
• Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

  2014cited by this paper
• Matching chelators to radiometals for radiopharmaceuticals.

  2014cited by this paper
• Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives

  2014cited by this paper
• Antitumor immunity induced after α irradiation.

  2014cited by this paper
• Organoid cultures for the analysis of cancer phenotypes.

  2014cited by this paper
• Transgenic mouse strains as platforms for the successful discovery and development of human therapeutic monoclonal antibodies.

  2014cited by this paper
• What is the Role of the Bystander Response in Radionuclide Therapies?

  2013cited by this paper
• PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

  2013cited by this paper
• Highly reactive trans-cyclooctene tags with improved stability for Diels-Alder chemistry in living systems.

  2013cited by this paper
• Pamphlet No . 24 : Guidelines for Quantitative 131 I SPECT in Dosimetry Applications

  2013cited by this paper
• Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results

  2013cited by this paper
• Mapping biological behaviors by application of longer-lived positron emitting radionuclides.

  2013cited by this paper
• MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications

  2013cited by this paper
• Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics.

  2013cited by this paper
• Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy

  2013cited by this paper
• A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels–Alder Click Chemistry

  2013cited by this paper
• Molecular Pathways: Targeted α-Particle Radiation Therapy

  2012cited by this paper
• Molecular engineering of antibodies for therapeutic and diagnostic purposes

  2012cited by this paper
• Cerenkov imaging - a new modality for molecular imaging.

  2012cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• A mechanistic compartmental model for total antibody uptake in tumors.

  2012cited by this paper
• Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

  2012cited by this paper
• Practical theoretic guidance for the design of tumor-targeting agents.

  2012cited by this paper
• Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.

  2011cited by this paper
• A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

  2011cited by this paper
• Astatine-211: production and availability.

  2011cited by this paper
• Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody

  2011cited by this paper
• A novel platform to produce human monoclonal antibodies

  2011cited by this paper
• Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.

  2011cited by this paper
• Inbred Strains Should Replace Outbred Stocks in Toxicology, Safety Testing, and Drug Development

  2010cited by this paper
• Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

  2010cited by this paper
• Multiplexed imaging in cancer diagnosis: applications and future advances.

  2010cited by this paper
• Have we overestimated the benefit of human(ized) antibodies?

  2010cited by this paper
• The immunogenicity of humanized and fully human antibodies

  2010cited by this paper
• Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

  2010influential reference
• [Antibody therapy in cancer].

  2010cited by this paper
• MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy*

  2010cited by this paper

• Spatial resolution and image quality of radionuclides for PET imaging.

  2026cites this paper
• Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction

  2026cites this paper
• Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier.

  2025cites this paper
• CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma

  2025cites this paper
• MIB guides: [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging

  2025cites this paper
• Cadherin-17 as a target for the immunoPET of adenocarcinoma

  2024influential citation
• Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives

  2024cites this paper
• Electrostatic properties of human germlines and biodistribution of small biologics

  2024cites this paper
• Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis

  2024cites this paper
• Radioimmunotheragnosis in Cancer Research

  2024cites this paper
• Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.

  2024cites this paper
• Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?

  2024cites this paper
• Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy

  2023cites this paper
• Applications of radiolabeled antibodies in neuroscience and neuro-oncology.

  2023cites this paper
• De Novo Approaches to the Solid-Phase Separation of Titanium(IV) and Scandium(III): Translating Speciation Data to Selective On-Bead Chelation toward Applications in Nuclear Medicine.

  2023cites this paper
• Recombinant Cells as a Tool for Evaluating the Specific Activity of Radiolabeled Antibodies against Endoglin (CD105)

  2023cites this paper
• Biologicals as theranostic vehicles in paediatric oncology.

  2022cites this paper
• Multiplexed imaging in oncology

  2022cites this paper
• Advances in Surface Enhanced Raman Spectroscopy for in Vivo Imaging in Oncology

  2022cites this paper
• Comparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules

  2022cites this paper
• Enzymatic Methods for the Site-Specific Radiolabeling of Targeting Proteins

  2021influential citation
• Nuclear Imaging of Endogenous Markers of Lymphocyte Response

  2021cites this paper
• Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors

  2021influential citation
• A Review of Recent and Emerging Approaches for the Clinical Application of Cerenkov Luminescence Imaging

  2021cites this paper
• Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer

  2021cites this paper
• The Radiochemistry of Zirconium

  2020cites this paper
• Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management

  2020cites this paper
• Production of the next-generation positron nuclide zirconium-89 (89 Zr) guided by Monte Carlo simulation and its good quality for antibody labeling.

  2020cites this paper
• Antibody Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers.

  2020cites this paper
• Design Strategies and Medicinal Applications of Metal-Peptidic Bioconjugates.

  2020cites this paper
• Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

  2020cites this paper
• Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.

  2019cites this paper